Target intelligence / Profile preview

KCNJ2 antisense RNA 1 (KCNJ2-AS1)

Target: KCNJ2-AS1
Molecular classification: Long noncoding RNA (lncRNA), Antisense RNA, Other (non-protein coding RNA)

Overview

KCNJ2 antisense RNA 1 (KCNJ2-AS1) is a long noncoding antisense RNA transcribed from the genomic region overlapping or adjacent to the KCNJ2 potassium channel gene. As an antisense lncRNA, KCNJ2-AS1 may regulate the expression of KCNJ2 and potentially other genes by modifying chromatin structure, influencing transcription, or affecting post-transcriptional processing. The exact function of KCNJ2-AS1 remains unclear, as public gene databases currently list its involvement mainly in gene regulation rather than direct participation in canonical protein-coding pathways. While antisense lncRNAs have established roles in cancer biology and epigenetic control, direct disease associations and drug interactions for KCNJ2-AS1 specifically are not well documented in the current literature.

Other names: FLJ36644KCNJ2 antisense RNA 1 (head to head)KCNJ2 antisense RNA 1 (non-protein coding)KCNJ2-AS1

Mechanism of action

If targeted by ASOs: - RNase H-mediated RNA degradation - Inhibition of translation - Alteration of splicing or polyadenylation

Biological functions

Regulation of gene expression (mainly at the transcriptional and post-transcriptional level)Modulation of chromatin state (histone modification, chromatin remodeling)Epigenetic regulation (can influence methylation and histone modifications of nearby genes)Other (roles may vary by tissue and disease context)

Disease associations

Cancer (lncRNAs and antisense RNAs frequently play roles in cancer development and progression by regulating gene expression; however, for KCNJ2-AS1, specific cancer association requires direct publication evidence)Cardiovascular disease (KCNJ2-AS1 is located near KCNJ2, a gene whose protein product is a cardiac ion channel, but no direct evidence for KCNJ2-AS1 in heart disease was found in the results)Other (potential, but specific diseases not firmly established for KCNJ2-AS1)

Safety considerations

Challenges in targeting lncRNAs include off-target effects (due to sequence similarity to other RNAs), delivery of ASOs or siRNAs to specific tissues, and unknown systemic consequences of modulating gene regulationlncRNAs can regulate multiple genes; thus, therapeutic interventions may have unpredictable pleiotropic effects.

Interacting drugs

No drugs are currently listed as interacting directly with KCNJ2-AS1. However, antisense oligonucleotides (ASOs) are a class of investigative therapeutics that can be used to target lncRNAs for degradation or modulation

Biomarkers

No validated clinical biomarkers for KCNJ2-AS1 are listed. lncRNAs, including antisense RNAs, are under investigation as biomarkers for cancer and other diseases, but KCNJ2-AS1 is not a widely used clinical biomarker.

Beyond the preview

Go deeper on KCNJ2 antisense RNA 1 (KCNJ2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KCNJ2 antisense RNA 1 (KCNJ2-AS1).

Explore the full profile